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Abstract
Background: Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous
(HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients. APR-246 (PRIMA-1MET) is the first
clinical-stage compound that reactivates mutant p53 protein by refolding it to wild type conformation, thus inducing
apoptosis. APR-246 has been tested as monotherapy in a Phase I/IIa clinical study in hematological malignancies and
prostate cancer with promising results, and a Phase Ib/II study in combination with platinum-based therapy in ovarian
cancer is ongoing. In the present study, we investigated the anticancer effects of APR-246 in combination with
conventional chemotherapy in primary cancer cells isolated from ascitic fluid from 10 ovarian, fallopian tube, or
peritoneal cancer patients, 8 of which had HGS cancer.
Methods: Cell viability was assessed with fluorometric microculture cytotoxicity assay (FMCA) and Combination
Index was calculated using the Additive model. p53 status was determined by Sanger sequencing and single
strand conformation analysis, and p53 protein expression by western blotting.
Results: We observed strong synergy with APR-246 and cisplatin in all tumor samples carrying a TP53 missense
mutation, while synergistic or additive effects were found in cells with wild type or TP53 nonsense mutations.
Strong synergy was also observed with carboplatin or doxorubicin. Moreover, APR-246 sensitized TP53 mutant
primary ovarian cancer cells, isolated from a clinically platinum-resistant patient, to cisplatin; the IC50 value of
cisplatin decreased 3.6 fold from 6.5 to 1.8 μM in the presence of clinically relevant concentration of APR-246.
Conclusion: These results suggest that combination treatment with APR-246 and DNA-damaging drugs could
significantly improve the treatment of patients with TP53 mutant HGS cancer, and thus provide strong support
for the ongoing clinical study with APR-246 in combination with carboplatin and pegylated liposomal
doxorubicin in patients with recurrent HGS cancer.
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Background
Ovarian, fallopian tube, and peritoneal high-grade serous
(HGS) cancers share many characteristics and are clinic-
ally managed in the same way [1]. The cancer is classified
based on characteristics like main tumor burden and
immunohistological pattern. Ovarian cancer is the most
common tumor in this group. Accumulated evidence sug-
gests that HGS cancer found in these tissues shares a
similar origin and pathogenesis, pointing out the fallopian
tube as the origin in the majority of cases [2, 3]. HGS can-
cer is the most malignant form of ovarian cancer and
accounts for 70–80 % of deaths [4]. Despite intense re-
search to find novel treatments there has been minimal
improvement in overall survival of the patients for the
past decades [4]. Although most HGS patients respond
well to first-line treatment with platinum-based therapy,
acquired resistance to conventional cancer therapies and
high death rates remain a major challenge. Thus, novel
treatment strategies directed against cancer-specific tar-
gets are urgently needed.
Mutation in the TP53 gene, which encodes the tumor
suppressor protein 53 (p53), is an early event in the devel-
opment of HGS cancer. More than 96 % of patients with
HGS cancer have mutations in TP53, which supports the
idea that mutations in TP53 are driver mutations essential
for the early development of this disease [5]. TP53 muta-
tions are common also in other types of ovarian cancer
and occur in at least 60 % of all ovarian tumors [6]. p53
induces cell cycle arrest, senescence and/or apoptosis
upon various types of cellular stress, such as DNA dam-
age, oncogene activation, and hypoxia. Mutations in TP53
are identified in about 50 % of all tumors and are associ-
ated with increased resistance to chemotherapy and re-
duced survival in many tumor types [7, 8].
APR-246 is the first clinical phase small molecule that
has been shown to reactivate mutant or otherwise incor-
rectly folded p53-protein by promoting its active conform-
ation [9, 10]. It is a prodrug that is converted to the active
form MQ (2-methylenequinuclidin-3-one), a Michael ac-
ceptor that binds to mutant p53 and restores the active
wild type conformation, thus triggering apoptosis [9, 10].
APR-246 has been tested as monotherapy in a Phase I/IIa
clinical trial in patients with hematological malignancies
and prostate cancer, with encouraging results [11]. A
Phase Ib/II Proof of Concept study with APR-246 in com-
bination with carboplatin and pegylated liposomal doxo-
rubicin is ongoing in patients with recurrent TP53-mutant
HGS cancer.
We have previously demonstrated strong synergistic an-
ticancer effects with APR-246 and DNA-damaging drugs
in ovarian cancer cell lines with various p53 status [12].
Moreover, we and others have shown that APR-246 (or
the analog PRIMA-1) can sensitize p53 mutant chemore-
sistant cancer cell lines to cisplatin [12, 13]. However, cell
lines often show substantial differences from original
tumors. Indeed, pronounced differences between some
of the most commonly used HGS ovarian cancer cell
line models and the majority of HGS ovarian cancer
samples have been revealed [14, 15]. The aim of this
study was to investigate the anticancer effect of APR-
246 as single compound as well as in combination with
conventional chemotherapeutic drugs, platinum com-
pounds and doxorubicin, in primary cancer cells isolated
from ascites (i.e., accumulated fluid in the abdominal




– APR-246, also called PRIMA-1MET (2-hydroxy-
methyl-2-methoxymethyl-1-azabicyclo [2, 2, 2]
octan-3-one) (Batch No. GF707504, Syngene)
– Cisplatin (Product No. 020345, Ebewe or Product
No. 146262, Hospira)
– Carboplatin (Product No. 136164, Hospira)
– Doxorubicin (Product No. 021361, Teva)
Primary cancer cells
Cancer cells isolated from ascitic fluid of 10 evaluable
patients were included in the study. Written informed
consent was obtained before ascitic fluid was collected,
and the procedures were in agreement with the Swedish
law and ethical regulations. The research project was
approved by the local ethics committee at Karolinska
Institutet (Dnr 2012/1933-31), including scientific pub-
lishing, and is in accordance with the principles of the
Declaration of Helsinki. All samples were from patients
with serous adenocarcinoma and 8 of them fulfilled the
present criteria of high-grade serous type (Table 1) [16].
According to the recommendations described in the
Swedish National Guidelines for Ovarian Cancer, for all
patients diagnosed after January 1st, 2014, the histo-
pathological grading of ovarian serous carcinoma was
performed using a two-tier system [17]. For the patients
included in the study, and diagnosed before 2014, the
histological slides were not reevaluated. Nevertheless, the
pathological report was matched for the present criteria.
Specific information about diagnosis, histology, treatment,
and p53 status is listed in Table 1. 8 samples were from
patients who had previously received chemotherapy.
Ascites was drained by abdominal paracenthesis from
patients with ovarian, fallopian tube, or peritoneal cancer
as symptomatic treatment. The procedure resulted in
0.5–6 l of ascitic fluid/patient. Heparin (LEO 5000 IE/
Ky/ml, Lot: 015227-06/DG2741, Leo Pharma) was added
to each bag (5 ml/l ascites) prior to the ascites drainage.
0.5-3 l ascitic fluid was centrifuged in 50 ml Falcon tubes
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Table 1 Summary of results with APR-246 and cisplatin in primary cancer cells from the patients
Ascites
sample












1 Ovarian cancer stage III Poorly differentiated serous carcinomaa Yes Resistant 25 40* R280K (hom.) ++ SS
2 Cancer peritonei stage IV Serous carcinoma Yes Resistant 24 18 wt − S, Add
3 Ovarian cancer stage IC Serous carcinoma Yes Resistant 37 32 L111Q (het.) + S, SS
4 Ovarian cancer/Cancer
peritonei stage IV
Poorly differentiated serous carcinomaa Yes Resistant 18 3.2 P151H (het.) + SS
5 Cancer peritonei stage IIIC Serous adenocarcinoma, grade IIIa No Sensitive 22 16 C135Y (hom.) + SS
6 Tubar cancer stage IIIB Poorly differentiated serous
adenocarcinomaa
Yes Sensitive 12 17 C238F (het.) ++ SS
7 Ovarian cancer stage IIIC Poorly differentiated serous carcinomaa Yes Resistant 56d 45d E346* (het.) − S, Add
8 Cancer Peritonei stage IV Poorly differentiated serous carcinomaa No Sensitive 8.9 7.1 E204* (hom.) − SS
9 Ovarian cancer stage IIIC Poorly differentiated serous carcinomaa Yes Resistant 5.2 7.9 P278R (hom.) + SS
10 Ovarian cancer stage IIIC Medium-well differentiated serous
adenocarcinomaa,b
Yes Sensitive 8.0 17 Y163H (het.) + SS
Cell viability was assessed by the FMCA assay. Combination Index (CI) was calculated using the Additive model.
Diagnosis: The 10 samples included in the study were from patients diagnosed with ovarian, peritoneal, or fallopian tube cancer. Strong data suggest that high-grade serous (HGS) carcinomas found in these tissues
share a similar origin and pathogenesis pointing out the distal part of the fallopian tubes as the origin in the majority of cases [2, 3].
Histological description: The primary histopathological analysis of the samples in this study was performed using the previous grading system and heterogeneous criteria and not according to the present standard
where tumors are classified into low- and high-grade serous carcinomas.
aThese samples are classified as HGS carcinoma according to the current criteria [16]. Likely is also sample 3 with TP53 mutation HGS carcinoma.
bPatient 10 was later reoperated for distant metastasis and the histopathological analysis showed HGS tumor.
Platinum sensitivity: patients who relapse > 6 months are classified as platinum-sensitive; patient who relapse < 6 months are platinum-resistant.
p53 status: het. = heterozygous; hom. = homozygous; * = stop codon. The sequencing method used cannot distinguish homozygous from hemizygous mutations, neither can heterozygosity be distinguished from a
mixture of cells with wild type and mutant TP53.
p53 protein levels:− = not detected; + =medium; ++ = high.
Combination APR-246 cisplatin: Add = additive effect (CI = 1.0 ± 0.2); S = synergy (CI < 0.8); SS = strong synergy (CI < 0.5).
cThe dose-response curve of cisplatin levelled off and thus resulted in difficulty to determine the IC50 value.












at 200 g for 5 min (room temperature) and each cell
pellet was resuspended in 30 ml CO2-independent
medium (#18045-054, Gibco), supplemented with 5 %
heat inactivated fetal bovine serum (FBS) (#F7524,
Sigma), 1 mM L-glutamine (#7513, Sigma), and 5000u
streptomycin and 5 mg penicillin/ml (#P0781, Sigma).
To the bottom of each tube, 10 ml Ficoll paque plus
(Batch No. 17-1440-02, GE Healthcare) was added with
a syringe. The tubes were centrifuged at 510 g for
15 min. The tumor cell-rich fraction, in the interface
between the medium fraction and the Ficoll fraction,
was removed with a Pasteur pipette and transferred to
a fresh tube. The cells were washed three times in sup-
plemented CO2-independent medium and counted in
Bürker’s chamber. Most of the samples had cell aggre-
gates of various sizes which resulted in difficulties in
determining exact cell count. Samples 3 and 6 with large
aggregates were filtered through 100 μm filter. Cytospin
glasses were prepared (~10000 cells/well). Thereafter, the
remaining cells were viably frozen in 90 % FBS + 10 %
DMSO.
Assessment of cell viability
Cell viability was assessed by the fluorometric micro-
culture cytotoxicity assay (FMCA), which measures the
esterase activity of cells with intact plasma membrane
by hydrolysis of the nonfluorescent probe fluorescein
diacetate (FDA) to fluorescein [18]. The generated
fluorescence is proportional to the number of cells with
intact plasma membrane, i.e., viable cells.
96-well plates with v-shaped wells (# 249570, NUNC)
were prepared with test substances at 10x the desired
concentration. The substance plates were sealed with
microtiter tape and kept at -80 °C until used. The cell
suspension was seeded (10000 cells/well in a total vol-
ume of 200 μl) in thawed substance plates and incubated
for 72 h at 37 °C with 5 % CO2. After incubation, the
cell plates were washed and incubated with 100 μl per
well of 1 μl FDA (# F7278, Sigma)/ml physiological buffer
(Q2) [18] for 40 min at 37 °C with 5 % CO2. Thereafter,
the fluorescence generated (excitation 480 nm) was mea-
sured at 538 nm.
Analysis of synergy
Combination effects were analyzed using the Additive
model [19–21]. The model assumes a log-linear shape
of the dose-response curve, which is fairly valid if the
drug concentrations used cause effects in the steep part
of the dose-response curve [21]. In samples with two
co-incubated substances, a predicted cell viability (%) is
calculated according to the following formula: Pre-
dicted cell viability (%) = cell viability of substance 1 (%)
x cell viability of substance 2 (%) x 0.01. Combination
Index (CI) is then calculated as the measured cell
viability of the sample with two co-incubated sub-
stances divided by the predicted cell viability. CI 0.8–
1.2 is considered as an additive effect (the interval of
1.0 ± 0.2 is set to account for intra-assay variability). CI
< 0.8 is synergistic effect and CI > 1.2 sub-additive ef-
fect. If the measured cell viability for a combination of
two substances is higher than the cell viability for one
or both of the substances, the effect is considered an-
tagonistic. In this report, we have classified CI < 0.5 as
strong synergistic effect. If the predicted viability is very
low, the quote “measured viability/predicted viability”
may give false CI values. Thus, we decided to set a
lower limit of 5 % for the predicted viability.
TP53 sequencing and western blotting
For all samples used in the study, the TP53 gene was
analyzed by Sanger sequencing and single strand con-
formation analysis and the p53 protein expression by
western blotting. The TP53 gene status (exons 2–11)
was analyzed by PCR amplification and sequencing,
followed by single-strand conformation analysis (SSCA)
according to the original protocol [22], and samples
displaying gel mobility shifts were sequenced to con-
firm the nucleotide change.
Western blotting: Cells were lysed in RIPA buffer (2x
RIPA: 0,87766 g NaCl, 1 ml 100x Triton, 0.5 ml 20 %
SDS, 5 ml 1 M Tris pH 8.0 + H2O up to 50 ml) supple-
mented with protease inhibitor (#04906845001, Roche)
for 30 min on ice. After centrifugation the supernatant
was isolated and used for further analysis. Total protein
concentration was determined with the BCA-method.
Equal amount of protein from all samples was added to
2x Laemmli buffer (#161-0737, BioRad) supplemented
with 2-mercaptoethanol (#161-0710, BioRad, 1:20 in
the Laemmli buffer) in a 1:1 ratio, and boiled at 95 °C
for 5 min before separated by electrophoresis on a 4–
15 % TGX-gel (BioRad) and transferred to PVDF mem-
brane using a semi-dry trans blot system (BioRad). The
membranes were blocked in Tris-buffered saline con-
taining 5 % w/v nonfat dry milk and 0.1 % Tween-20,
followed by incubation with primary antibody overnight
at 4 °C, and with secondary antibody for 1 h at room
temperature.
Primary antibodies: anti-p53 antibody (#9282, Cell
Signaling), anti-p53 antibody (#FL-393, Santa Cruz),
anti-GAPDH antibody (#5632-1, clone EPR6256, Epi-
tomics). Secondary antibodies: HRP-conjugated anti-
bodies (#P 0447 or #P 044801-2, Dako). The proteins
were visualized by enhanced chemiluminescence sys-
tem (ECL prime, #RPN2232, VWR) and detected using
a CCD camera (LAS1000 Fujifilm Tokyo Japan). Dark
pixels were measured for quantification of protein
bands using ImageJ.
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TP53 sequencing and western blotting were performed
at the Department of Clinical and Experimental Medicine,
Linköping University (Dr. Peter Söderkvist).
Microscopic analysis of cells
May Grünwald-Giemsa stained cytospin slides were visu-
ally judged by an experienced cytopathologist (Manuel de
la Torre, Uppsala University Hospital). According to our
quality criteria, at least 70 % of all cells in a sample should
be cancer cells and the cell viability should be at least
70 %. All samples included in the study met these criteria.
For some samples immunostainings with anti-BER-EP4
antibody (# IR637, Dako) and anti-calretinin antibody
(clone NCL-L-CALRETININ, Novacasta) were needed in
order to discriminate between cancer cells and mesothelial
cells. The anti-BER-EP4 antibody stains all cells of epithe-
lial origin including ovarian cancer cells, whereas the anti-
calretinin antibody stains mesothelial cells. Secondary
staining was performed with Dako REAL EnVision Detec-
tion System (#K5007) and visualized with diaminobenzi-
dine (DAB) according to the kit.
Results
Characteristics of the patients
In this study, primary cancer cells isolated from ascitic
fluid from 10 patients were investigated. 8 patients had
previously received platinum-based chemotherapy. The
patients were diagnosed with ovarian, peritoneal, or fal-
lopian tube cancer and 8 of them fulfilled the current
histopathological criteria for HGS cancer (Table 1).
p53 status
As shown in Fig. 1, cancer cells from 7 patients possessed
TP53 missense mutations leading to the following substi-
tutions in the DNA-binding domain of p53: L111Q,
C135Y, P151H, Y163H, C238F, P278R, and R280K, re-
spectively. Two patients had nonsense mutations, and one
had wild type p53. p53 proteins accumulated at medium
or high levels in cells with missense mutations, while no
p53 protein was detected with anti-p53 antibody (#9282)
in cells carrying wild type or nonsense mutant TP53
(Fig. 1, Table 1). Similar results were obtained also with
another anti-p53 antibody (FL-393, data not shown).
Sensitivity of primary ovarian cancer cells to APR-246 and
conventional drugs
The sensitivity of primary ovarian cancer cells to APR-
246 and DNA-damaging drugs was investigated using
the FMCA cell viability assay. Fig. 2 shows that both
APR-246 and cisplatin decreased cell viability in a dose-
dependent manner. Table 1 summarizes the individual
IC50 values of APR-246 and the platinum drug cisplatin.
The mean IC50 value of APR-246 was 22 ± 4.9 μM and
that of cisplatin 20 ± 4.5 μM (mean ± SEM; n = 10
patients).
The sensitivity of the cisplatin analog carboplatin and
the anthracycline doxorubicin was also investigated. The
mean IC50 values of carboplatin and doxorubicin were
47 ± 15 μM and 5.9 ± 2.1 μM, respectively (mean ± SEM;
n = 5 patients). The individual IC50 values of carboplatin
ranged from 3.7 to 87 μM and those of doxorubicin
from 1.2 to 12 μM (data not shown).
Strong synergistic effects with APR-246 and DNA-
damaging drugs in primary ovarian cancer cells carrying
missense TP53 mutations
We then investigated combination effects of APR-246
and cisplatin in cancer cells with various p53 status. As
shown in Fig. 3a, strong synergistic effect (CI < 0.5) was
observed in cancer cells carrying homozygous R280K
p53. Table 1 summarizes the results from studies using
cancer cells from all 10 patients. Strong synergy with
APR-246 and cisplatin was found in all cancer cells
carrying TP53 missense mutations. In sample 3,
Fig. 1 Expression of p53 in primary ovarian cancer cells. The anti-p53 antibody used (polyclonal antibody #9282) binds strongly to the N-terminus
and weakly to the DNA-binding region of p53. * = stop codon, hom. = homozygous. het. = heterozygous. It should be noted that the sequencing
method used cannot distinguish between homozygous and hemizygous mutations. “het.” indicates that both wild type p53 and mutant p53 are
found in the sample, which can either be due to heterozygosity or heterogeneity in the sample with the presence of cells with different
p53 status
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Fig. 3 Strong synergy with APR-246 and cisplatin (a), carboplatin (b), or doxorubicin (c) in primary ovarian cancer cells. Cell viability was assessed by
FMCA assay after 72 h incubation with drugs. Additive model was used for analysis of combination effects. Combination Index (CI) values are presented
above the bars. CI < 0.8 indicates synergy and < 0.5 strong synergy. CI values < 0.8 are marked in red. The results shown are mean ± SEM (n = 2)
Fig. 2 Inhibition of cell viability by APR-246 (a) and cisplatin (b). Cell viability was assessed by the FMCA assay after 72 h incubation with drug.
The results shown are mean ± SEM; n = 10 patients
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synergistic effects (CI < 0.8) were also observed. Additive
or synergistic effects were found in cancer cells carrying
wild type TP53 or nonsense TP53 mutation in the tetra-
merization domain resulting in truncated E346* p53.
Strong synergy was observed in cells carrying the homo-
zygous nonsense TP53 mutation resulting in truncated
E204* p53.
Combination studies with APR-246 and carboplatin
(Fig. 3b) or doxorubicin (Fig. 3c) were performed in 2
samples carrying homozygous TP53 missense mutation
(sample 5 and 9). Strong synergistic effects with APR-246
in combination with carboplatin or doxorubicin were
obtained in cancer cells from both samples.
APR-246 sensitizes primary ovarian cancer cells to cisplatin
We also tested the ability of APR-246 to sensitize primary
cancer cells to cisplatin, using cells from a recurrent clinically
platinum-resistant patient carrying homozygous P278R mu-
tant TP53. Dose-response experiments with cisplatin alone
and in combination with various concentration of APR-246
were performed. As shown in Fig. 4, APR-246 sensitized the
primary cancer cells to cisplatin in a dose-dependent
manner; the IC50 value of cisplatin (with the partial effect
contribution from APR-246 subtracted) decreased 3.6-fold
from 6.5 to 1.8 μM in the presence of 8 μM APR-246.
Discussion
Most HGS tumors are detected at an advanced stage since
symptoms are usually not apparent until the cancer has
metastasized. The standard treatment of advanced ovarian
cancer is cytoreductive surgery followed by 6-8 cycles of
platinum compounds in combination with taxanes [23].
Many patients respond well to the first-line treatment but
most of the patients relapse. Second-line therapy can
prolong survival but is rarely curative. For platinum-
sensitive patients (i.e., those who relapse > 6 months)
treatment with carboplatin, in combination with pacli-
taxel, pegylated liposomal doxorubicin, or gemcitabine,
is the standard therapy [24]. For patients with platinum-
resistant disease (who relapse < 6 months) single agent
therapy with, e.g., pegylated liposomal doxorubicin, is the
standard treatment.
Platinum-based drugs have for decades been used for
effective treatment of many solid tumors, including
ovarian cancer [25, 26]. Cisplatin, the first member of
this class, has had a major impact on the treatment of
cancer but is also associated with side effects, including
nephrotoxicity. This led to the development of the less
toxic analog carboplatin [25]. Although platinum com-
pounds exert their anticancer effect by multiple mecha-
nisms, their primary mechanism of action is interaction
with DNA to form DNA-adducts, which leads to DNA
damage response and p53-dependent apoptosis. How-
ever, repeated treatment with platinum compounds leads
to a gradual decrease of the DNA damage response and
resistance to platinum drugs as well as cross-resistance
to other DNA-damaging drugs. The underlying mechan-
ism of platinum resistance is multifactorial and involves
Fig. 4 APR-246 sensitized primary ovarian cancer cells with TP53 mutation to cisplatin. The FMCA assay was used to assess cell viability after 72 h
incubation with drugs. This ascites sample was taken from a clinically platinum-resistant patient. The results shown are mean ± SEM (n = 2)
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drug-induced increase in intracellular glutathione (GSH)
levels leading to enhanced efflux of platinum compounds,
reduced drug uptake, increased drug inactivation, as well as
inactivation of the tumor suppressor protein p53 [26–29].
The mode of action of APR-246 as a p53-mutant tar-
geting compound is well documented, and the molecu-
lar mechanisms underlying the reactivation of mutant
p53 and induction of apoptosis are relatively well char-
acterized [9, 10, 30]. APR-246 is a prodrug that is con-
verted to MQ, a Michael acceptor that binds to cysteine
residues in mutant and/or unfolded p53 and promotes
correct folding. This induces activation of caspase-2
and expression of p53-target genes, including, PUMA,
NOXA, and BAX, leading to mitochondrial apoptosis
[9, 10, 30]. Recently, we have shown that MQ also binds
to cysteine residues in glutathione and thereby de-
creases intracellular free glutathione concentrations in
drug-resistant TP53-mutant ovarian cancer cells [12].
Moreover, APR-246 can bind to free cysteines leading
to inhibition of glutathione synthesis and to further de-
crease in intracellular glutathione concentration. APR-
246 can also trigger apoptosis in a p53-independent
manner by binding to thioredoxin reductase 1 (TrxR1)
and inducing ROS [9, 10, 12, 31]. This unique mechanism
of action of APR-246, targeting both p53 and glutathione,
probably underlies the outstanding synergistic effect as
well as the complete resensitization to cisplatin observed
with APR-246 in combination with cisplatin in drug-
resistant TP53mutant ovarian cancer cell lines [12].
In the present study we have investigated the effects of
APR-246 in combination with current therapy in primary
ovarian cancer cells isolated from ascitic fluid. Cancer cells
in ascites mirror most of the molecular characteristics of
cells in the primary tumor and at metastatic sites [32]. One
explanation for this may be that the metastatic process in
ovarian cancer is less complex than in most other types of
cancer, since ovarian cancer cells metastasize mainly via as-
cites and not via the blood system [32]. Ascites contains
single tumor cells and multicellular tissue-like aggregates,
which have reduced proliferation and limited drug penetra-
tion resulting in decreased susceptibility to chemotherapy
[33]. The composition of ascites has been reported to differ
between untreated and treated patients since evolution of
cancer stem cell-like cells occurs in response to platinum
treatment [34].
We observed strong synergistic effects with APR-246
in combination with cisplatin in cancer cells from all
tumor samples with TP53 missense mutations, while
additive or synergistic effects were observed in samples
with wild type TP53 or nonsense mutation resulting in
truncated E346* p53. Notably, we observed synergy in
cancer cells from both treated and untreated patients.
Further, we showed that APR-246 sensitizes primary
ovarian cancer cells from a TP53 mutant drug-resistant
HGS patient to cisplatin. The cancer cells were isolated
from ascites of a chemotherapy-treated patient carrying
homozygous P278R mutant p53. APR-246 decreased the
IC50 value of cisplatin in a dose-dependent manner, with
a 3.6-fold decrease from 6.5 to 1.8 μM in the presence
of 8 μM APR-246.
We also observed strong synergy with APR-246 in com-
bination with the cisplatin analog carboplatin as well as
with the anthracycline doxorubicin in the two samples
tested, carrying homozygous TP53 mutations (resulting in
C135Y and P278R mutant p53, respectively). The main
mechanisms of action of doxorubicin are inhibition of
DNA and RNA synthesis by intercalation between base
pairs of the DNA/RNA strands, and interference with
the topoisomerase II enzyme, leading to double-strand
breaks [35]. This triggers the DNA damage response
and activation of the p53 pathway leading to apoptosis
or senescence. Although it has been reported that in-
activation of p53 can cause resistance to anthracyclines
[36], the significance of p53 status for sensitivity to
anthracyclines is less clear than its significance for sen-
sitivity to platinum compounds.
In the present study, cancer cells from 7 of totally 10
patients had TP53 missense mutations in the DNA bind-
ing region, two carried nonsense mutations, and one
sample had wild type TP53. Two of the mutations have
not previously been reported in ovarian cancer (L111Q
and E346*). All 7 missense mutations are predicted to
severely affect the function of p53 according to The p53
Web Site [6]. Most of them show transactivation activity
below 15 % as compared to wild type p53 on 8 different
p53-regulated promoters (p21, MDM2, BAX, AIP,
GADD45, Noxa, p53R2, and 14-3-3-S). Prediction of
loss of activity based on phylogenetic conservation
(SIFT) and other biochemical properties (Provean and
Condel) indicates that all these mutations are deleteri-
ous. Notably, some recent studies indicate that patients
with advanced ovarian/HGS cancer with various TP53
mutations have different survival outcomes [37, 38].
All samples with cancer cells carrying missense mu-
tations had medium or high levels of p53, while no p53
protein was detected in cells with wild type or non-
sense mutations. High levels of p53 have been sug-
gested to contribute to strong apoptosis-inducing
effect of APR-246 [39]. Missense mutations in TP53
are common in HGS ovarian cancer, but the disease is
also characterized by the highest frequency of TP53
nonsense or frameshift mutations in any cancer (15 %
of TP53 mutant tumors) [40].
Conclusion
In the present study, we observed strong synergistic effect
with APR-246 in combination with standard chemother-
apy in primary cancer cells isolated from HGS cancer
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patients with various TP53 missense mutations. Moreover,
we show for the first time that APR-246, at clinically rele-
vant concentrations, sensitizes primary ovarian cancer
cells isolated from a drug-resistant TP53 mutant patient
to cisplatin. Drug-resistant HGS cancer patients have very
poor prognosis since only palliative treatment is available.
Our results suggest that combination treatment with
APR-246 and DNA-damaging drugs has the potential to
significantly improve the treatment of therapy-refractory
HGS ovarian cancer.
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